Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Exelixis's Zanzalintinib?
Zanzalintinib is a small molecule commercialized by Exelixis, with a leading Phase III program in Metastatic Colorectal Cancer. According to...
Data Insights
Risk adjusted net present value: What is the current valuation of Exelixis's Zanzalintinib?
Zanzalintinib is a small molecule commercialized by Exelixis, with a leading Phase III program in Metastatic Colorectal Cancer. According to...